Latest news
Changes to the Board of Directors
announces that the Chairman, Anders P. Wiklund, and the board members Annette Clancy and Hilde H. Steineger, have decided to resign from the Board of Directors of Clavis Pharma ASA.
CEO Olav Hellebø to leave Clavis Pharma
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that Olav Hellebø will leave the position as CEO of the company effective 20 May by mutual agreement.
Minutes from Extraordinary General Meeting
The Extraordinary General Meeting elected Martin Nes and Øystein Stray Spetalen as new directors.
Clavis Pharma - First Quarter Results 2013
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces its results for the first quarter 2013, and including significant post-period events.
